These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 22018018)

  • 1. Normal and malignant megakaryopoiesis.
    Wen Q; Goldenson B; Crispino JD
    Expert Rev Mol Med; 2011 Oct; 13():e32. PubMed ID: 22018018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human megakaryocyte production: cell biology and clinical considerations.
    Gewirtz AM; Hoffman R
    Hematol Oncol Clin North Am; 1990 Feb; 4(1):43-64. PubMed ID: 2179214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection.
    Papadantonakis N; Matsuura S; Ravid K
    Blood; 2012 Aug; 120(9):1774-81. PubMed ID: 22767499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis.
    Abbonante V; Karkempetzaki AI; Leon C; Krishnan A; Huang N; Di Buduo CA; Cattaneo D; Ward CM; Matsuura S; Guinard I; Weber J; De Acutis A; Vozzi G; Iurlo A; Ravid K; Balduini A
    Am J Hematol; 2024 Mar; 99(3):336-349. PubMed ID: 38165047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
    Vyas P; Roberts I
    Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
    Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
    Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNAs can increase the efficiency of ex vivo platelet generation.
    Emmrich S; Henke K; Hegermann J; Ochs M; Reinhardt D; Klusmann JH
    Ann Hematol; 2012 Nov; 91(11):1673-84. PubMed ID: 22763947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Megakaryopoiesis: regulation of platelet production by thrombopoietin].
    Vainchenker W; Besancenot R; Favale F
    Bull Acad Natl Med; 2013 Feb; 197(2):395-406. PubMed ID: 24919369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Megakaryocytes and platelets in myeloproliferative disorders.
    Briere J; Kiladjian JJ; Peynaud-Debayle E
    Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Megakaryopoiesis in chronic myeloproliferative disorders].
    Nagasawa T
    Rinsho Ketsueki; 1993 May; 34(5):551-6. PubMed ID: 8315826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
    Thiele J; Funke S; Holgado S; Choritz H; Georgii A
    Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.
    Deutsch VR; Tomer A
    Br J Haematol; 2013 Jun; 161(6):778-93. PubMed ID: 23594368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
    Thiele J; Kvasnicka HM; Schmitt-Gräff A
    Pathologe; 2002 Nov; 23(6):426-32. PubMed ID: 12436295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.
    Ling T; Crispino JD; Zingariello M; Martelli F; Migliaccio AR
    Expert Rev Hematol; 2018 Mar; 11(3):169-184. PubMed ID: 29400094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological characteristics of megakaryocytes: specific lineage commitment and associated disorders.
    Sun L; Hwang WY; Aw SE
    Int J Biochem Cell Biol; 2006; 38(11):1821-6. PubMed ID: 16730215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors.
    Guo Y; Niu C; Breslin P; Tang M; Zhang S; Wei W; Kini AR; Paner GP; Alkan S; Morris SW; Diaz M; Stiff PJ; Zhang J
    Blood; 2009 Sep; 114(10):2097-106. PubMed ID: 19372257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryopoiesis and thrombopoiesis: an update on cytokines and lineage surface markers.
    Yu M; Cantor AB
    Methods Mol Biol; 2012; 788():291-303. PubMed ID: 22130715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.